Lead Product(s) : IVW-1001
Therapeutic Area : Ophthalmology
Study Phase : Phase I/II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
IVIEW Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 in Dry Eye
Details : IVW-1001, a novel TRPM8 agonist delivered via ophthalmic eyelid wipes, is evaluated for treating dry eye disease signs and symptoms.
Brand Name : IVW-1001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 17, 2024
Lead Product(s) : IVW-1001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?